KRd Therapy Outshines VRd in Newly Diagnosed Multiple Myeloma
A groundbreaking study has revealed that KRd therapy, a combination of carfilzomib, lenalidomide, and dexamethasone, significantly improves progression-free survival in patients with newly diagnosed multiple myeloma compared to the traditional VRd treatment. This finding, presented at the 67th ASH Annual Meeting, highlights a potential paradigm shift in the treatment of this disease.
The COBRA trial, a phase 3 study, compared KRd and VRd in patients with a Frailty Score of less than 2.1, stratified by cytogenetic risk and history of venous thromboembolism. The results showed that KRd reduced the risk of progression or death by 43% in the intent-to-treat population, with a median follow-up of 53 months. The median PFS was not reached in the KRd group, compared to 48.8 months in the VRd arm.
The benefits of KRd were observed across all cytogenetic subgroups, with statistically significant improvements in PFS in the standard-risk group. In this subgroup, 27% of patients treated with KRd experienced progression or death, compared to 40% with VRd. The high-risk cohort also showed favorable outcomes with KRd, with 31% vs. 48% of patients experiencing progression or death.
The study's presenting author, Dominik Dytfeld, MD, PhD, emphasized the superior efficacy of KRd, noting that it achieved both co-primary endpoints of MRD-negative CR at 12 months and PFS. KRd demonstrated deeper responses, with higher rates of complete response and minimal residual disease negativity, while also showing anticipated toxicity profiles with higher rates of neutropenia and cardiac adverse effects, but less neuropathy.
The COBRA trial's design included a detailed analysis of transplant-eligible and transplant-ineligible patients, revealing distinct patterns in PFS favoring KRd among those eligible for autologous stem cell transplant. In this subgroup, KRd reduced the risk of progression or death by 60%, with only 23% of patients experiencing progression or death, compared to 45% in the VRd arm.
Safety outcomes showed that both regimens were associated with high rates of adverse events, but specific toxicity patterns differed. Grade 3 or higher AEs occurred in 73% of KRd-treated patients and 62% of VRd-treated patients, with any-grade AEs nearly universal across both cohorts. Treatment discontinuation due to AEs was more common in the KRd arm, but fatal AEs were infrequent and similar in both groups.
The study's findings suggest that KRd therapy offers a promising approach for patients with newly diagnosed multiple myeloma, particularly in those eligible for autologous stem cell transplant. Further evaluation of KRd-based induction regimens is warranted to optimize treatment outcomes and improve patient care.
